Clin2
NCT02325674Likely a fitRecruiting

Metreleptin safety and effectiveness registry

Generalised LipodystrophyPartial Lipodystrophy

Treatments studied

Part of Genetic & congenital, Hormones & metabolism, Skin clinical trials.

This registry follows people who are already taking metreleptin (a medicine for certain rare conditions) to better understand its long-term safety and how well it works in everyday use. It may help you and other patients by building real-world evidence about this treatment.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
100 people
Ages
Any age
Study type
Observational

Who can take part

  • You take metreleptin from regular (commercial) supply now or started it before joining
  • You can sign a written consent form to join the registry
  • You are coming from a previous metreleptin study and you are continuing or restarting metreleptin through regular supply
  • You are not taking an investigational (study-only) medicine as part of another clinical trial

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06484868Recruiting· Phase 4
Study of metreleptin for partial lipodystrophy

This trial tests an open-label study of metreleptin in people with partial lipodystrophy, a condition where fat is lost from some areas of the body. The goal is to see if the drug can help manage related health problems.

Lille
NCT05470504Recruiting· Phase 2
Pegvisomant for severe insulin resistance from rare fat or gene problems

This Phase 2 study tests pegvisomant, a medicine that blocks growth hormone, to see if it can improve severe insulin resistance in people with a specific genetic cause or a rare fat distribution condition. If you fit the rare diagnosis, the study may help clarify whether growth-hormone blocking can improve blood sugar and related health markers.

Bethesda, Maryland
NCT06679270Recruiting· Phase 3
Long-term safety study of metreleptin for partial lipodystrophy

This study tests the long-term safety of metreleptin for people with partial lipodystrophy. It is for those who already completed a related study and want to continue treatment.

Birmingham, Alabama
NCT07165028Recruiting· Phase 3
Study of new drugs for fatty liver with scarring

This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.

Tuscaloosa, Alabama
NCT05419037Recruiting
Study of pregnancy outcomes in people with lipodystrophy

This study looks at how pregnancy goes and what birth outcomes happen in women with lipodystrophy, comparing those who used metreleptin during pregnancy versus those who did not. It also collects information and blood samples from the children so researchers can better understand the effects of metreleptin during pregnancy.

Bethesda, Maryland
NCT06305182Recruiting· Phase 2
Metreleptin for Anorexia Nervosa

This study tests a drug called metreleptin (a version of a hormone that helps regulate appetite and weight) in people hospitalized for anorexia nervosa. It may help with weight restoration and mood.

Zurich, Canton of Zurich

Hear when a new Partial Lipodystrophy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.